Vast Therapeutics, founded with a mission to address the global health crisis of drug-resistant infections, is a preclinical biotechnology company specializing in nitric oxide-based drugs. The company's vision is to combat severe chronic lung infections and improve patient outcomes using their proprietary technology. Their primary focus is on developing treatments for conditions such as bronchiectasis, NTM disease, and cystic fibrosis, targeting a market that urgently needs innovative solutions.

Notable figures associated with Vast Therapeutics include its scientific advisory board, comprised of experts in airway immunology and infectious diseases. The company has garnered attention for its innovative approach, evidenced by its selection to present at the American Thoracic Society's Respiratory Innovation Summit. Vast's impact lies in its potential to revolutionize treatment protocols for drug-resistant infections, contributing significantly to global health and economic stability.